OpenResearchAlpha

JNCI: Journal of the National Cancer Institute · 4 Nov 2026

Modeling neoadjuvant treatment plus additional therapy effects on US population breast cancer mortality

Xuelin Huang, Yisheng Li, Swarnavo Sarkar, Sawal Acharya, Hui Huang, Rick Groeneweg, Eugenio J Gil Quessep, Nicole Lipa, Juhee Song, Yuanliang Yang, Liyang Sun, Ying Lu, Harald Weedon-Fekjaer, Kathryn P Lowry, Christina H Chapman, Jinani Jayasekera, Clyde Schechter, Harry J de Koning, Brandy M Heckman-Stoddard, Natasha K Stout, Sandra J Lee, Nicolien T van Ravesteyn, Oguzhan Alagoz, Allison W Kurian, Sylvia K Plevritis, Amy Trentham-Dietz, Jennifer L Caswell-Jin, Jeanne S Mandelblatt, Donald A Berryh-index 9

0
Citations
no database records one yet
0
Citations in 2026
so far
9
Leading author's h-index
Donald A Berry, in QAI's scholar index
0
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Abstract Background Neoadjuvant therapy provides assessment of therapeutic response and the opportunity to guide additional post-surgical adjuvant treatment (NAPAT) for women with residual breast cancer. This treatment approach may reduce breast cancer mortality compared with adjuvant therapy or neoadjuvant treatment without added response-guided therapy (No NAPAT). However, the benefit of this approach has not been quantified in the US population. Methods We used six well-established Cancer Intervention and Surveillance Network (CISNET) models to assess the potential impact of NAPAT vs. No NAPAT for women eligible for chemotherapy on breast-cancer mortality from 2018-2030 in the US. We simulated multiple US female birth-cohorts using common screening and treatment inputs derived from clinical trials, large national observational studies and national cancer registries. For years post-2018, we assumed trends in treatments and screening continued as in 2018. Results are presented as a mean and range across models for overall and molecular subtype-specific breast cancer mortality. Results The models projected that use of neoadjuvant plus additional adjuvant therapy could decrease breast cancer mortality rates to 23.0/100,000 by year 2030 (range across models 20.6-25.4), equaling a 10.5% (6.5%-14.0%) reduction in mortality compared with No NAPAT. Reductions varied by molecular subtype: 30.7% (18.5-38.1%) for women with triple negative tumors, 27.9% (15.6-34.3%) for ER-negative/HER2-positive tumors, 15.4% (10.8-23.6%) for ER-positive/HER2-positive, and essentially no effect 1.3% (-1.0 ̶ 4.0%) for ER-positive/HER2-negative tumors. Conclusion Among women eligible for chemotherapy, use of neoadjuvant plus adjuvant therapy could decrease overall US breast-cancer mortality, even with no further therapeutic advances.

What the data shows

  • No database records a citation yet, as is usual for a paper this new.
  • Donald A Berry has the highest h-index among the authors (9).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (29)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (0)

What it cites, from open citation data, with Crossref's record of each.

No references in the open citation data yet.